A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
A Phase 1b Study of Venetoclax in Combination With Pembrolizumab in Subjects With Previously Untreated NSCLC Whose Tumors Have High PD-L1 Expression
Sponsor: AbbVie
Terminated
Company Decision
This PHASE1 trial investigates Cancer and Non Small Cell Lung Cancer and is currently terminated or withdrawn. AbbVie leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2021 — Jul 2024 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Feb 2021 — Mar 2021 [monthly]
Suspended PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Suspended PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Aug 2020 — Dec 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .